99mTc-LHRH in tumor receptor imaging

Hao,Dawei; Sun,Lingfei; Hu,Xiang; Hao,Xiaowen

doi:10.3892/ol.2017.6246

99mTc-LHRH in tumor receptor imaging

Authors:
- Dawei Hao
- Lingfei Sun
- Xiang Hu
- Xiaowen Hao
View Affiliations

Affiliations: Department of Radiotherapy, Xuzhou Central Hospital, Xuzhou, Jiangsu 221009, P.R. China
Published online on: May 24, 2017 https://doi.org/10.3892/ol.2017.6246
Pages: 569-578
Copyright: © Hao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Detection of gonadotropin-releasing hormone (GnRH) also known as luteinizing hormone‑releasing hormone (LHRH) in the relevant tumor tissue and normal tissues and organs in vivo expression was investigated. To examine the method of direct radio labeling of LHRH by 99mTc with relatively high radiochemical purity and stability, screening the best labeling conditions, to establish a simple and reliable method of preparation of 99mTc-LHRH was undertaken. The detection of radioisotope-labeled LHRH distribution in mice, LHRH receptor imaging for the study and treatment of cancer basis were evaluated. i) Immunohistochemical staining test was used in 23 patients with hepatocellular carcinoma (HCC), 20 patients with breast cancer, 10 patients with prostate cancer, 20 patients with lung cancer, 20 patients with endometrial cancer tumor cells and normal tissue LHRH-R De Biaoda levels; ii) pre-tin method use direct labeling of LHRH, marking completion of saline or human serum were added at room temperature, the chromatography was measured at different times, to calculate the rate of labeled product and the radiochemical purity of the label, in vivo observation of its stability, and comparative analysis of selected optimal condition; iii) rat pituitary cell membrane protein, the product of in vitro radio-receptor marker analysis, through the saturation and inhibition experiments, was used to test its receptor binding activity; iv) Ch-T method labeled 125I‑LHRH, tail vein injection of normal mice at different times were sacrificed, blood and major organs were determined and calculated per gram organization percentage injected dose rate (%, ID/g). Detected by immunohistochemistry in 23 cases of HCC in the LHRH‑positive rate was 82.61%, in the corresponding normal tissues, the positive rate was 15%; 20 cases of breast cancer positive rate of 95%, the corresponding normal tissues, the positive rate was 20%; 10 cases of prostate cancer positive rate of 70%, the corresponding normal tissues, the positive rate of 40%; 20 cases of lung cancer positive rate of 85%, the corresponding normal tissues, the positive rate of 15.79%; 20 cases of endometrial cancer positive rate of 80% in the corresponding normal tissues was 16.67% positive. 99mTc‑LHRH mark was 97.9-100.0%, the radiochemical purity of 93.9-96.4%, marking the reaction gel content of <5%. Great product receptor marker analysis showed 99mTc-LHRH with saturable receptor binding characteristics and inhibition, and high affinity, RT = 23.2174 pmol, KD = 0.4348 nmol; intravenous injection of 131I-LHRH within 72 h after the mice rapidly cleared the blood radioactivity, the major radioactive accumulation in the liver and kidneys and by the liver, renal clearance, and other tissues and organs of the radioactivity gradually decreased with time. In conclusion, i) the liver, lung, breast, prostate, endometrial cancer exist in both LHRHR; ii) 99mTc-LHRH preparation is simple, rapid, radiochemical purity product obtained higher marks, better stability, no further purification; and iii) LHRH 99mTc labeled, still has a high receptor binding ability, biological activity; and has an ideal and realistic dynamics in animals, there is hope, as with the clinical value of imaging agent of GnRH receptors.

View Figures

View References

1	Yuan B, Zhang J and Zhang YQ: Research progress of relation between GnRH and its receptor and tumors. Prog Anatomical Sci. 8:367–371. 2002.(In Chinese).
2	Jia PY and Wang YX: Application of gonadotropin-releasing hormone and its receptor in cancer therapy. J Int Pharm Res. 36:179–183. 2009.(In Chinese).
3	Yin H, Cheng KW, Hwa HL, Peng C, Auersperg N and Leung PC: Expression of the messenger RNA for gonadotropin-releasing hormone and its receptor in human cancer cell lines. Life Sci. 62:2015–2023. 1998. View Article : Google Scholar : PubMed/NCBI
4	Wen S, Schwarz JR, Niculescu D, Dinu C, Bauer CK, Hirdes W and Boehm U: Functional characterization of genetically labeled gonadotropes. Endocrinology. 149:2701–2711. 2008. View Article : Google Scholar : PubMed/NCBI
5	Xie J: The current development and prospect of tumor molecular nuclear medicine. Kawakita medical report. 24:315–318. 2009.(In Chinese).
6	Ji Q, Zhou J and Huang W: Immunohistochemical and in situ hybridization study of thyroid gonadotropin-releasing hormone receptor in rats. Chinese J Histochem Cytochem. 11:241–243. 2002.(In Chinese).
7	Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Hölzel F, Schulz KD and Schally AV: High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res. 53:5439–5446. 1993.PubMed/NCBI
8	Schottelius M, Berger S, Poethko T, Schwaiger M and Wester HJ: Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency. Bioconjug Chem. 19:1256–1268. 2008. View Article : Google Scholar : PubMed/NCBI
9	Mankoff DA, Link JM, Linden HM, Sundararajan L and Krohn KA: Tumor receptor imaging. J Nucl Med. 49 Suppl 2:149S–163S. 2008. View Article : Google Scholar : PubMed/NCBI
10	Gründker C, Völker P and Emons G: Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase. Endocrinology. 142:2369–2380. 2001. View Article : Google Scholar : PubMed/NCBI
11	Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, Fischer D, Sommer HL, Conrad B, Ortmann O, et al: Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 29:2334–2341. 2011. View Article : Google Scholar : PubMed/NCBI
12	Emons G, Schröder B, Ortmann O, Westphalen S, Schulz KD and Schally AV: High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab. 77:1458–1464. 1993. View Article : Google Scholar : PubMed/NCBI
13	Moreau JP, Delavault P and Blumberg J: Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy. Clin Ther. 28:1485–1508. 2006. View Article : Google Scholar : PubMed/NCBI
14	Rose A, Froment P, Perrot V, Quon MJ, LeRoith D and Dupont J: The luteinizing hormone-releasing hormone inhibits the anti-apoptotic activity of insulin-like growth factor-1 in pituitary alphaT3 cells by protein kinase C alpha-mediated negative regulation of Akt. J Biol Chem. 279:52500–52516. 2004. View Article : Google Scholar : PubMed/NCBI
15	Szende B, Srkalovic G, Schally AV, Lapis K and Groot K: Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression. Cancer. 65:2279–2290. 1990. View Article : Google Scholar : PubMed/NCBI
16	Greco F and Vicent MJ: Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev. 61:1203–1213. 2009. View Article : Google Scholar : PubMed/NCBI
17	Duncan R: Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 6:688–701. 2006. View Article : Google Scholar : PubMed/NCBI
18	Eidne KA, Flanagan CA, Harris NS and Millar RP: Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J Clin Endocrinol Metab. 64:425–432. 1987. View Article : Google Scholar : PubMed/NCBI
19	Barda Y, Cohen N, Lev V, Ben-Aroya N, Koch Y, Mishani E, Fridkin M and Gilon C: Backbone metal cyclization: novel 99mTc labeled GnRH analog as potential SPECT molecular imaging agent in cancer. Nucl Med Biol. 31:921–933. 2004. View Article : Google Scholar : PubMed/NCBI
20	Seitz S, Buchholz S, Schally AV, Weber F, Klinkhammer-Schalke M, Inwald EC, Perez R, Rick FG, Szalontay L, Hohla F, et al: Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125. BMC Cancer. 14:8472014. View Article : Google Scholar : PubMed/NCBI
21	Rusiecki JA, Holford TR, Zahm SH and Zheng T: Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status. Cancer Detect Prev. 29:419–426. 2005. View Article : Google Scholar : PubMed/NCBI
22	Van Den Bossche B and Van de Wiele C: Receptor imaging in oncology by means of nuclear medicine: current status. J Clin Oncol. 22:3593–3607. 2004. View Article : Google Scholar : PubMed/NCBI
23	Imai A, Takagi A, Horibe S, Takagi H and Tamaya T: Fas and Fas ligand system may mediate antiproliferative activity of gonadotropin-releasing hormone receptor in endometrial cancer cells. Int J Oncol. 13:97–100. 1998.PubMed/NCBI
24	Cai W and Chen X: Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression. Front Biosci. 12:4267–4279. 2007. View Article : Google Scholar : PubMed/NCBI
25	Virgolini I, Traub T, Novotny C, Leimer M, Füger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, et al: Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curs Pharm Des. 8:1781–1807. 2002. View Article : Google Scholar
26	Meko JB, Doherty GM, Siegel BA and Norton JA: Evaluation of somatostatin-receptor scintigraphy for detecting neuroendocrine tumors. Surgery. 120:975–983. 1996. View Article : Google Scholar : PubMed/NCBI
27	Katsuno M, Adachi H, Doyu M, Minamiyama M, Sang C, Kobayashi Y, Inukai A and Sobue G: Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med. 9:768–773. 2003. View Article : Google Scholar : PubMed/NCBI
28	Reisinger I, Bohuslavitzki KH, Brenner W, Braune S, Dittrich I, Geide A, Kettner B, Otto HJ, Schmidt S and Munz DL: Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study. J Nucl Med. 39:224–227. 1998.PubMed/NCBI
29	Thakur ML, Marcus CS, Saeed S, Pallela V, Minami C, Diggles L, Le Pham H, Ahdoot R and Kalinowski EA: 99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans. J Nucl Med. 41:107–110. 2000.PubMed/NCBI
30	Fekete M, Zalatnai A, Comaru-Schally AM and Schally AV: Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas. 4:521–528. 1989. View Article : Google Scholar : PubMed/NCBI
31	Szepeshazi K, Schally AV, Groot K and Halmos G: Effect of bombesin, gastrin-releasing peptide (GRP)(14–27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters. Int J Cancer. 54:282–289. 1993. View Article : Google Scholar : PubMed/NCBI
32	Peremans K, Cornelissen B, Van Den Bossche B, Audenaert K and Van de Wiele C: A review of small animal imaging planar and pinhole spect Gamma camera imaging. Vet Radiol Ultrasound. 46:162–170. 2005. View Article : Google Scholar : PubMed/NCBI
33	Friess H, Berberat P, Schilling M, Kunz J, Korc M and Büchler MW: Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. J Mol Med (Berl). 74:35–42. 1996. View Article : Google Scholar : PubMed/NCBI
34	Schottelius M, Berger S, Poethko T, Schwaiger M and Wester HJ: Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency. Bioconjug Chem. 19:1256–1268. 2008. View Article : Google Scholar : PubMed/NCBI
35	Reubi JC and Maecke HR: Peptide-based probes for cancer imaging. J Nucl Med. 49:1735–1738. 2008. View Article : Google Scholar : PubMed/NCBI
36	Medina RA and Owen GI: Glucose transporters: expression, regulation and cancer. Biol Res. 35:9–26. 2002. View Article : Google Scholar : PubMed/NCBI
37	Wang R: Clinical outlook for radio-immunity imaging. Int J Radiat Med Nucl Med Volume. 13:40–42. 1989.
38	Wang R, Zhang C, Yu L and Guo Y: Clinical application of radioimmunoimaging with 99mTc-BDI-1 in the diagnosis of bladder cancer. Chin Med J (Engl). 113:396–399. 2000.PubMed/NCBI
39	Vriesendorp HM and Vriesendorp FJ: A review of the intravenous administration of radiolabeled immunoglobulin G to cancer patients. High or low protein dose? Cancer Biother Radiopharm. l8:35–46. 2003. View Article : Google Scholar
40	Kang JH and Chung JK: Molecular-genetic imaging based on reporter gene expression. J Nucl Med. 49 Suppl 2:164S–179S. 2008. View Article : Google Scholar : PubMed/NCBI
41	Cai W and Chen X: Multimodality molecular imaging of tumor angiogenesis. J Nucl Med. 49 Suppl 2:113S–128S. 2008. View Article : Google Scholar : PubMed/NCBI
42	de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, Bugaj JE, Erion J, Schmidt M, Srinivasan A, et al: [177Lu-DOTA0,Tyr3]octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer. 92:628–633. 2001. View Article : Google Scholar : PubMed/NCBI
43	Khan TS, Sundin A, Juhlin C, Långström B, Bergström M and Eriksson B: 11C-metomidate PET imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging. 30:403–410. 2003. View Article : Google Scholar : PubMed/NCBI
44	Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, Ritter J, Lewis JS, Welch MJ and Siegel BA: Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum. 51:1641–1648. 2008. View Article : Google Scholar : PubMed/NCBI
45	Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, Dempsey JF, Perez CA, Purdy JA and Welch MJ: A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 49:117l–1182. 2001. View Article : Google Scholar
46	Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA and Welch MJ: Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys. 55:1233–1238. 2003. View Article : Google Scholar : PubMed/NCBI
47	Suzuki T, Nakamura K, Kawase T and Kubo A: Monitoring of response to radiation therapy for human tumor xenografts using 99mTc-HL91 (4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime). Ann Nucl Med. 17:131–138. 2003. View Article : Google Scholar : PubMed/NCBI
48	Mochizuki T, Kuge Y, Zhao S, Tsukamoto E, Hosokawa M, Strauss HW, Blankenberg FG, Tait JF and Tamaki N: Detection of apoptotic tumor response in vivo after a single dose of chemotherapy with 99mTc-Annexin V. J Nucl Med. 44:92–97. 2003.PubMed/NCBI